Catatan sumber primer
PenentuHasil topline
Aquestive melaporkan hasil studi faktor manusia & PK Anaphylm yang positif
Perusahaan mengumumkan hasil positif dari studi validasi faktor manusia dan studi farmakokinetik untuk Anaphylm sublingual film. Data ini mendukung rencana pengajuan ulang NDA ke FDA untuk pengobatan reaksi alergi Tipe 1, termasuk anafilaksis.
Fakta utama
- Diajukan
- 10 Agu 2026, 11.05
- Peristiwa
- Hasil topline
- Arah
- Positif
- Perusahaan
AQSTAquestive- Aset
- epinephrine
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
- Kalender
- Hasil uji klinis · 1 Jul 2026 · Positif
Kutipan sumber
aqst-20260810 0001398733 false 0001398733 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2026 Aquestive Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-38599 82-3827296 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 30 Technology Drive Warren , NJ 07059 ( 908 ) 941-1900 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) Not Applicable (Former name or former address, if changed since last report) ______________________
Selengkapnya tentang aset ini
Penentu
13 Mei 2026
20.04
AQSTAquestiveMaterial
30 Mar 2026
11.44
AQSTAquestivePenentu
9 Jan 2026
12.18
AQSTAquestivePenentu
5 Nov 2025
21.04
AQSTAquestivePenting
8 Okt 2025
11.23
AQSTAquestiveAquestive: dua paten baru memperluas perlindungan Anaphylm hingga 2037